CytoSorbents™

HELPING REDUCE DEADLY UNCONTROLLED INFLAMMATION IN HOSPITALIZED PATIENTS WORLDWIDE

NASDAQ: CTSO

Investor Presentation

October 2017
Safe Harbor Statement

This presentation contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "intend," "target," "will," "is likely," "would," "may," or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements are found at various places throughout this presentation and include information concerning possible or assumed future results of our operations; business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future operations, future cash needs, business plans and future financial results, and any other statements that are not historical facts. Unless otherwise indicated, the terms “CytoSorbents,” “Company,” “we,” “us” and “our” refer to CytoSorbents Corporation. Any or all of the forward-looking statements included in this presentation are not guarantees of future performance and may turn out to be inaccurate. These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. Although these expectations may change, we are under no obligation to inform you if they do. Actual events or results may differ materially from those contained in the forward-looking statements. The following factors, among others, could cause our actual results to differ materially from those described in a forward-looking statement: our history of losses; potential fluctuations in our quarterly and annual results; competition, inability to achieve regulatory approval for our device, technology systems beyond our control and technology-related defects that could affect the companies’ products or reputation; risks related to adverse business conditions; our dependence on key employees; competition for qualified personnel; the possible unavailability of financing as and if needed; and risks related to protecting our intellectual property rights or potential infringement of the intellectual property rights of third parties. This list is intended to identify only certain of the principal factors that could cause actual results to differ from those discussed in the forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of the applicable presentation. You are referred to a discussion of important risk factors detailed in the Company’s Form 10-K filed with the Securities and Exchange Commission on March 3, 2017 and other reports and documents filed from time to time by us, which are available online at www.sec.gov.
CytoSorbents is a leader in critical care immunotherapy.

Leading the prevention or treatment of life-threatening inflammation in the ICU and cardiac surgery using CytoSorb® blood purification.
CytoSorbents At a Glance

- NASDAQ-traded (CTSO): ~$6.00 per share
- CytoSorb®, is E.U. approved, with 27,000+ treatments; distributed in 44 countries
- Trailing 12-month sales of $10.4M vs $6.0M a year ago, blended gross margins = 65%
- 80 employees with international footprint across two wholly-owned subsidiaries
  - CytoSorbents Medical, Inc - New Jersey, USA
    - Headquarters, ISO 13485 manufacturing, QA/QC, R&D
  - CytoSorbents Europe GmbH: International sales office - Berlin, Germany
- Strategic Partnerships with Fresenius Medical Care, Terumo, Biocon, and Dr. Reddy’s
- Strong government support with $20M+ in grants, contracts, other non-dilutive funding
- Pursuing U.S. approval of CytoSorb® in cardiac surgery
- Russell Microcap Index listed with coverage by Cowen, HCW, Aegis, B Riley, Maxim & Zacks

✓ With continued international growth, expect to achieve operating profitability in 2018
✓ Plan to begin U.S. pivotal, registration trial for CytoSorb this year, pending FDA review
Leadership Background

Phillip Chan, MD, PhD – Chief Executive Officer and President
Former Partner at the $80M NJTC Venture Fund, leading life science investments for 5 years. Co-founder of Andrew Technologies, commercializing its HydraSolve™ lipoplasty device in the U.S. MD/PhD from Yale School of Medicine, internal medical residency at the Beth Israel Deaconess Medical Center at Harvard.

Vincent Capponi, MS - Chief Operating Officer
20+ years experience in the medical device, pharmaceutical and imaging fields. Led the first regulatory approval for the heparin flush syringe, used worldwide in hospitals, and managed manufacturing of > 1 million units/week

Kathleen Bloch, MBA, CPA – Chief Financial Officer
20+ years as CFO of private and public companies. Former Laureate Biopharma CFO, a contract biopharmaceutical manufacturer, and CFO of Silverline Windows, a $750M revenue window manufacturing company with 9 manufacturing plants nationally

Eric Mortensen, MD, PhD - Chief Medical Officer
25 years leading clinical trials for key programs at Pfizer, GSK, and Merck. Most recently Vice President & Therapeutic Area Clinical Head for Inflammation and Immunology at Pfizer, leading the company’s global late-stage development organization for programs in inflammation including studies for Enbrel and Xeljanz

Christian Steiner, MD – Vice President of Sales and Marketing
15+ years experience in sales and marketing of extracorporeal therapy and critical care sales at Teraklin for MARS, the first liver failure dialysis technology, and at Pulsion Medical (hemodynamic monitoring)

Christopher Cramer, MS, MBA – Vice President of Business Development
15+ years experience in business development and commercial experience. Former Senior Director of New Venture Development at Johnson & Johnson, and previously at PwC Consulting
Uncontrolled Inflammation is Deadly

 Millions Die Of Uncontrolled Deadly Inflammation Each Year

- Sepsis
- Trauma
- Influenza
- Burn Injury
- Lung Injury
- Pancreatitis
- Surgical Complications
- Liver Failure
- Cytokine Release Syndrome
Massive Inflammation Causes Organ Failure

Organ failure occurs when vital organs stop working, causing nearly half of all deaths in the ICU.

Little can be done to prevent or treat organ failure today.
No Ideal Options to Treat Severe Inflammation

<table>
<thead>
<tr>
<th>Anti-Inflammatory (too weak)</th>
<th>Immunosuppressive (too strong)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSAIDs</td>
<td>Corticosteroids</td>
</tr>
<tr>
<td>Aspirin</td>
<td>Chemotherapy</td>
</tr>
<tr>
<td>Anti-cytokine antibodies</td>
<td>Organ transplant</td>
</tr>
<tr>
<td>Anti-integrin antibodies</td>
<td>Anti-rejection drugs</td>
</tr>
<tr>
<td>Anti-oxidants</td>
<td>Radiation</td>
</tr>
<tr>
<td></td>
<td>Immune system ablation</td>
</tr>
<tr>
<td></td>
<td>Anti-leukocyte Abs</td>
</tr>
</tbody>
</table>
Anti-Inflammatory (too weak)
- NSAIDs
- Aspirin
- Anti-cytokine antibodies
- Anti-integrin antibodies
- Anti-oxidants

Immunosuppressive (too strong)
- Corticosteroids
- Chemotherapy
- Organ transplant
- Anti-rejection drugs
- Radiation
- Immune system ablation
- Anti-leukocyte Abs
CytoSorb® Removes the Fuel to the Fire

- CytoSorb® targets the $20+ billion opportunity in critical care and cardiac surgery
- Approved in the European Union as the only specifically approved extracorporeal cytokine filter
- Broad indication for use where cytokines are elevated
- Removes cytokines and many other inflammatory mediators such as free hemoglobin, bacterial toxins, myoglobin, and activated complement
- Safe and well-tolerated: ~27,000 delivered treatments, up from 14,000 a year ago

*CytoSorb is not yet approved in the U.S.
Patented Blood Purification Technology

The underlying blood purification technology is based on biocompatible, highly porous polymer beads that act like tiny sponges to remove harmful substances from blood.

- Protected by 32 issued US patents and multiple applications pending worldwide
- Manufactured at our ISO 13485 certified facility in New Jersey
- One of the highest grade medical sorbents on medical market today
CytoSorb is “Plug and Play”

Compatible with Existing Dialysis and Heart-Lung Machines

- Place a temporary dialysis catheter in a major vein
- Connect the device to a standard dialysis, ECMO, or heart-lung machine found in hospitals worldwide
- Pump blood out of the body and through the cartridge
- The polymer beads directly contact blood and remove unwanted or toxic substances
- “Purified” blood is pumped back into the patient
- Can treat 70+ total blood volumes per 24 hour treatment
- Each treatment uses a new cartridge
Goal: To Prevent or Treat Organ Failure

Improve Patient Outcome and Survival

Decrease Costs Of ICU and Patient Care

The Potential to Revolutionize Critical Care Medicine

- Sepsis
- ARDS
- Burn Injury
- Trauma
- Pancreatitis
- Influenza
- Surgical
Case Report: Toxic Shock Syndrome

- 17 year old man suffered an injury to his ankle and unexpectedly began to develop fever

- He rapidly deteriorated and was hospitalized the next day at a major hospital in Rotterdam, Netherlands where antibiotics were started immediately. He continued to decline and was admitted to the ICU where he went into shock.

- Patient became globally red and swollen, and was suspected to have toxic shock syndrome.

- Surgical exploration of the injured ankle revealed a Staphylococcal infection, confirming the diagnosis

- Patient was still in shock and developed respiratory failure requiring intubation

- Patient was started on CytoSorb and within 5 minutes his blood pressure increased

- After three hours of treatment, the patient's swelling and redness had resolved

- Total CytoSorb® treatment was only 14 hours. Patient went on to fully recover

* These pictures are examples of scalding skin syndrome but are not of the patient
The World Needs **CytoSorb®**
## Blood Purification Alternatives

<table>
<thead>
<tr>
<th>Sorbents</th>
<th>HMCO Filters</th>
<th>Coupled Plasma Filtration Adsorption</th>
<th>Therapeutic Plasma Exchange</th>
</tr>
</thead>
<tbody>
<tr>
<td>CytoSorb</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CytoSorb - CytoSorbents</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EMiC2 - Fresenius</td>
<td></td>
<td></td>
<td>CPFA - Bellco</td>
</tr>
<tr>
<td>I.M.P.A.C.T - Hemolife</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SepteX - Baxter/Gambro</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Theranova - Baxter</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
CytoSorb

27,000+ Treatments

44 Countries Worldwide with E.U.

- Critical Care
  21,000+

- Cardiac Surgery
  6,000+

United States

- Cardiac Surgery

REFRESH 2
Start
2H 2017

$10.4M Sales
60+ Investigator Initiated Studies.
More than two dozen peer reviewed publications in the past 12 months
CytoSorb® Is Like a High Margin Razorblade

- CytoSorbents is a pure play high margin disposables business where the CytoSorb “razorblade” is fully compatible with the existing installed base of “razor” ICU dialysis and ECMO machines, and heart-lung machines in the operating room.

- Blended gross margins are 65%, but with economies of scale and manufacturing efficiencies, this is expected to increase.

- Average Direct Selling Price is approximately $1,000 per cartridge.

- Approximately 1 - 10 cartridges are typically used per patient. Open heart surgery uses 1-2 cartridges, treatment of sepsis uses 3-5 cartridges. An entire course of treatment for sepsis is roughly the cost of 1 day in the ICU.

- In Germany, 400 hospitals have >400 beds. Each of these hospitals is expected to see 300 to 600 sepsis patients per year. At 3-5 cartridges per patient:
  - Revenue per patient = ~$3,000-5,000
  - Potential revenue per hospital = $1-3M for sepsis alone

- One hospital in Germany had achieved sales of >$1M in 2016, demonstrating early validation of this model.
CytoSorbents’ direct sales force focused on most major university and public hospitals in Germany, Austria, Switzerland, Belgium and Luxembourg. German market alone is $1.0-1.5 billion.
Dedicated Reimbursement In Germany

- CytoSorb has achieved a permanent, dedicated reimbursement code in Germany – our most important market and the largest medical device market in Europe
- We believe this has the potential to validate the importance of our therapy to physicians in the country
- Was achieved rapidly through the initiative and strong support of several major medical societies across different medical specialties
- Retroactive to January 1, 2017, the new code has resulted in higher reimbursement to many hospitals, compared to the more generic code we have used. This has already had a positive effect on sales from a number of these hospitals in Germany. We expect direct sales momentum to accelerate as more hospitals negotiate higher reimbursement for CytoSorb
CytoSorb® Distributed in 44 Countries
Companies listed here are used simply as examples of companies in these respective verticals. We make no other representations as to our relationship with any of these companies.

Four Major Partnerships, Potential for More

**Critical Care or Catheters**
- BARD
- Teleflex
- angiodynamics
- Mallinckrodt

**Cardiac Surgery**
- LivaNova
- MAQUET GETINGE GROUP
- Medtronic
- TERUMO

**Renal Dialysis**
- STAGE
- NIPRO
- Davita
- B BRAUN
- NIKKISO
- GAMBRO

**Blood Transfusion**
- macopharma
- GRIFOLS
- FRESENIUS KABI
- TERUMO BCT

**Pharma and Biotech**
- Johnson & Johnson
- AMGEN
- Celgene
- Biocon
- Roche
- Abbvie
- sanofi aventis
- Dr. Reddy’s

Partnered with leading multinational corporations:
Fresenius Medical Care, Terumo Cardiovascular, Biocon Ltd, and Dr. Reddy’s Laboratories

* Companies listed here are used simply as examples of companies in these respective verticals. We make no other representations as to our relationship with any of these companies.
Expanded Fresenius Partnership

- CytoSorbents renewed and expanded its partnership with Fresenius Medical Care in January 2017

- Extension on exclusive distribution of CytoSorb for critical care applications in France, Poland, Denmark, Norway, Sweden, and Finland through 2019

- Guaranteed minimum quarterly orders and payments of CytoSorb evaluable every 1.5 years

- Co-marketing agreement across all of the countries where CytoSorb is sold, where possible
  - Will add to the “effective” sales force in each country
  - Fresenius is providing written endorsement of CytoSorb for the multiFiltrate platform

We are launching our co-marketing effort in 5 countries and plan to ramp up to other countries soon
• Entered into a multi-country strategic partnership with Terumo Cardiovascular Group, a global leader in medical devices for cardiac and vascular surgery

• Initial exclusive distribution of CytoSorb® CPB Procedure Pack for intra-operative use during cardiac surgery in France, Denmark, Norway, Sweden, Finland, and Iceland

• Launched December 2016

• We believe this strategic partnership opens the door to potential expansion to other countries, such as Japan – the second largest medical device market in the world
Respiratory failure is often caused by excessive inflammation causing capillary leak syndrome in the lungs – “drowning from inside out”

Mechanical ventilation for respiratory failure is dangerous: oxygen toxicity, pressure and volume trauma on lungs, complications like ventilator acquired pneumonia, pneumothorax, and ventilator dependence

Extracorporeal membrane oxygenation (ECMO) is a supportive care therapy that is increasing in popularity as an alternative to mechanical ventilation as a way to provide gas exchange, and sometimes hemodynamic support, in critically-ill patients

ECMO is typically used as a rescue therapy for those failing mechanical ventilation

Both standard mechanical ventilation and ECMO do not directly address the underlying cause of disease, only helping keep the patient alive

Therapeutic-ECMO, or the combination of ECMO with CytoSorb, has been used to reduce cytokines and other inflammatory mediators in 1,000+ treatments as a lung-preservation strategy for gas exchange. We recently launched a specific ECMO kit enabling safe and rapid connection of CytoSorb to ECMO
CAR-T Cell Immunotherapy and CRS

• CAR-T cell cancer immunotherapy is one of the most promising treatments for blood cancers. However, ~40-50% of patients develop cytokine release syndrome (CRS), a cytokine storm that can lead to rapid organ failure and potentially death.

• CytoSorb® was specifically designed to control cytokine storm and cytokine release syndrome (CRS) and has already successfully treated a dozen cases of the closely related disease hemophagocytic lymphohistiocytosis (HLH).

• We believe that CytoSorb® represents a unique and easy to administer rescue therapy for CAR-T cell and other immunotherapies as second line to tocilizumab, but before steroids.

• In March 2017, the pioneer of CAR T-cell immunotherapy, Dr. Carl June at University of Pennsylvania, joined our Scientific Advisory Board. His program, licensed by Novartis, and named Kymriah, was recently FDA approved, potentially paving the way for a fast track for CytoSorb.
Solid Organ Rehabilitation for Transplant

- ~120,000 solid organs were transplanted in 2014, < 10% of the global need

- Transplanted kidneys accounted for two-thirds of all transplants but 20% of donated kidneys are discarded because they do not meet organ donor criteria

- Other solid organs, particularly the lungs, have similar issues

- Cytokine storm and severe inflammation in the donor can compromise the health of donated organs, putting them at risk of graft failure after transplant, and decreased long term survival

- We have entered into a co-development agreement with Aferetica, the developer of the Perlife platform for organ rehabilitation that will incorporate one of our specifically branded proprietary sorbent cartridges

- The Perlife system is expected to launch in Italy later this year, and in select European countries in 2018
Heart disease is the leading cause of death worldwide driven by smoking, unhealthy lifestyles, and an aging population.

- ~1M cardiac surgeries performed annually in U.S. and E.U.
  - Coronary artery bypass graft surgery
  - Valve repair or replacement
  - Heart or lung transplantation
  - Congenital defect repair
  - Aortic reconstruction

Complex cardiac surgeries require long heart-lung machine pump times, resulting in:

- Hemolysis and free hemoglobin
- Inflammatory mediators, cytokines, and activated complement

Severe inflammation, nitric oxide scavenging, and reduced blood flow can lead to kidney, lung, and/or heart failure in many patients following surgery.
U.S. REFRESH 1 Trial
REduction in FREe Hemoglobin

• 46-patient, eight-center trial evaluating the safety and efficacy of intra-operative use of CytoSorb® in a heart-lung machine during elective, non-emergent complex cardiac surgery with heart-lung machine time ≥ 3 hours

• Working with major cardiac surgery centers
  – Baylor and Texas Heart Institute
  – Baystate Medical Center
  – Columbia University
  – Cooper University Hospital
  – University of Kentucky
  – University of Maryland
  – University of Pennsylvania
  – University of Pittsburgh

• First RCT using CytoSorb in high risk cardiac surgery
  • Demonstrated safety
  • Identified valve replacement patients who are the highest levels of peak pfHb
  • Demonstrated that CytoSorb significantly reduces pfHb by 35-40% and activated complement during treatment in this population

• Data from the REFRESH 1 Trial was selected for podium presentation at the American Association of Thoracic Surgery (AATS) conference in May 2017 and was submitted for publication

<table>
<thead>
<tr>
<th>CPB Length</th>
<th>Mean Reduction of pfHb (mg/dL)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.0</td>
<td>35 mg/dL</td>
<td>0.09</td>
</tr>
<tr>
<td>3.5</td>
<td>48 mg/dL</td>
<td>0.05</td>
</tr>
<tr>
<td>4.0</td>
<td>61 mg/dL</td>
<td>0.05</td>
</tr>
<tr>
<td>4.5</td>
<td>74 mg/dL</td>
<td>0.07</td>
</tr>
</tbody>
</table>
U.S. REFRESH 2 Pivotal Trial

- Plan to meet with the FDA shortly to confirm the clinical trial strategy and trial design for REFRESH 2 cardiac surgery, with goal to start trial 2H 2017

- REFRESH 2 is expected to be similar in design to REFRESH 1, but enriched with patients undergoing valve replacement patients, who have the highest levels of pfHb and at greatest risk for organ injury

- Preliminary trial design, pending discussions with the FDA:
  - Plan to start with core sites from REFRESH 1
  - 300-500 patient, 20-25 center randomized, controlled PMA trial
  - Primary and secondary clinical and cost-effectiveness endpoints: Progression to acute kidney injury (AKI), incidence of stroke, time on mechanical ventilation, hemodynamic stability, days in the ICU
  - Enrollment expected to complete within 2 years at 0.5 patients/month/site
  - $10-12M cost spread out over 3 years – potential for strategic partner support
  - Targeting 2019 completion, potential 2020 FDA approval
Quarterly Product Sales

CytoSorb® Product Sales

$3,041,012

$2,612,801

$2,143,116

$1,852,670

$1,597,449

$1,500,000

$1,495,590

$1,314,659

$1,031,761

$871,150

$663,233

$569,243

$473,112

$1,071,459

$1,273,969

$203,561

$131,769

$87,960

$13,679

Trailing Twelve Months Product Sales

Over the past three years, the compound growth rate of return ("CAGR") on product sales was 81%
Driving Toward Operating Breakeven

Trailing Twelve Months Key Performance Indicators

- **Product Revenue**
- **Gross Margin**
- **Fixed Operating Expenses**

(Excluding non-cash, clinical and certain variable expenses.)
The Company is Well-Capitalized

### Working Capital as of

<table>
<thead>
<tr>
<th></th>
<th>6/30/17</th>
<th>3/31/17</th>
<th>12/31/16</th>
<th>12/31/15</th>
<th>12/31/14</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current Assets:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and short-term investments</td>
<td>$16,402</td>
<td>$3,240</td>
<td>$5,245</td>
<td>$7,509</td>
<td>$5,550</td>
</tr>
<tr>
<td>Grants and accounts receivable, net</td>
<td>2,059</td>
<td>1,732</td>
<td>1,433</td>
<td>649</td>
<td>819</td>
</tr>
<tr>
<td>Inventories</td>
<td>890</td>
<td>858</td>
<td>834</td>
<td>1,191</td>
<td>538</td>
</tr>
<tr>
<td>Prepaid expenses and other current assets</td>
<td>390</td>
<td>451</td>
<td>316</td>
<td>512</td>
<td>700</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td>19,741</td>
<td>6,281</td>
<td>7,828</td>
<td>9,861</td>
<td>7,607</td>
</tr>
<tr>
<td><strong>Current Liabilities</strong>(1):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable</td>
<td>1,581</td>
<td>1,660</td>
<td>1,330</td>
<td>685</td>
<td>698</td>
</tr>
<tr>
<td>Accrued expenses and other current liabilities</td>
<td>1,602</td>
<td>1,608</td>
<td>2,115</td>
<td>723</td>
<td>825</td>
</tr>
<tr>
<td>Current maturities of long-term debt</td>
<td>2,000</td>
<td>1,250</td>
<td>833</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deferred revenue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td><strong>Total current liabilities</strong></td>
<td>5,183</td>
<td>4,518</td>
<td>4,278</td>
<td>1,408</td>
<td>1,524</td>
</tr>
<tr>
<td><strong>Net Working Capital</strong></td>
<td>$14,558</td>
<td>$1,763</td>
<td>$3,550</td>
<td>$8,453</td>
<td>$6,083</td>
</tr>
</tbody>
</table>

(1) Excludes warrant liability, a current liability that does not have cash implications.

### Cap Table 6/30/2017

<table>
<thead>
<tr>
<th>Fully Diluted Common Shares</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>28,133,986</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Options</td>
<td>3,868,407</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Warrants</td>
<td>1,038,560</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restricted Stock Unit Awards</td>
<td>110,003</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>33,150,956</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Upcoming Milestones

• Ongoing progress in international sales

• Operating profitability targeted in 2018

• Potential new partnerships and expansion of existing partnerships

• FDA filing for cardiac surgery trial

• Q4 2017 initiation of pivotal REFRESH 2 study

• Publications of clinical and research data

• Greater investor awareness through investor meetings, conferences, non-deal roadshows
CytoSorbents Investment Summary

CytoSorbents is strongly positioned and on track to have our strongest year ever

• Established, well-run U.S. medtech but with a biotech profile, nearing critical mass

• Strategically positioned and addressing some of the largest, most visible, unmet medical needs worldwide in critical care, cardiac surgery, cancer immunotherapy, and others

• Potentially highly profitable “razorblade” in someone else’s “razor” business model

• Significant CytoSorb® sales growth and expected gross margin expansion and near-term operating profitability

• Excellent validation by customers, partners, and government agencies

• Undiscovered by most investors, but positioned for broader awareness

• Visibility on multiple exits for investors
Providing Hope
in a helpless situation

HELPING PATIENTS SURVIVE CRITICAL ILLNESSES WORLDWIDE

NASDAQ: CTSO
Dr. Phillip Chan, MD, PhD – CEO
pchan@cytosorbents.com